Advertisement

Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.

09:15 EDT 24th May 2013 | BioPortfolio

Summary of "Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique."

Febuxostat is used in the treatment of hyperuricemia and gout. Several impurities were detected in Febuxostat drug substance. Impurities were identified with the help of LC-MS/MS and were characterized after synthesis by IR and NMR. Reverse phase gradient system was used with Kromasil C18, 150mm×4.6mm, 5μm particle size column for the separation of impurities. Q-TOF mass spectrometer with electrospray ionization (ESI) source was used and operated in ESI positive mode, which gives exact mass up to four decimal places and fragmentation with mass accuracy, it is useful for the identification of impurities. Four impurities were identified as amide, sec-butyl, des-cyano and des-acid in Febuxostat drug analog. These impurities were further confirmed by NMR and FT-IR spectral data.

Affiliation

Unimark Remedies Ltd., 337-Kerala Nalasarovar Road, Ahmedabad 382220, Gujarat, India. mustakkadivar@yahoo.com

Journal Details

This article was published in the following journal.

Name: Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Pages: 749-57

Links

Medical and Biotech [MESH] Definitions

Metabolic Detoxication, Drug

Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.

Drug Incompatibility

The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed)

Receptors, Drug

Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.

Substance Withdrawal Syndrome

Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.

Tissue Distribution

Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.

PubMed Articles [ 14155 Associated PubMed Articles listed on BioPortfolio]

Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.

This paper describes identification and characterization of a process-related impurity of meprobamate drug substance observed in HPLC-UV method. Forced degradation studies were carried out under acidi...

Identification, isolation and characterization of a new degradation product in sultamicillin drug substance.

A new degradant of sultamicillin drug substance was found during the gradient reverse phase HPLC analysis of stability storage samples. The level of this degradant impurity was observed up to 1.0%. Th...

Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.

An unknown impurity was detected in deferasirox drug substance by a newly developed high performance liquid chromatography (HPLC) method. The unknown impurity was identified by liquid chromatography-t...

Detection, identification and quantification of a new de-fluorinated impurity in casopitant mesylate drug substance during late phase development: an analytical challenge involving a multidisciplinary approach.

During late phase development of the selective NK1 receptor antagonist casopitant mesylate, a de-fluorinated impurity was discovered and quantified by an orthogonal analytical approach, using NMR and...

Effect of Zn impurity in K(0.8)Fe(2-δ-x)Zn(x)Se(2).

A series of K(0.8)Fe(2-δ-x)Zn(x)Se(2) single-crystal samples with nominal compositions 0 ≤ x ≤ 0.05 were grown and their physical properties were measured in order to study the effect of Zn i...

Clinical Trials [ 2665 Associated Clinical Trials listed on BioPortfolio]

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

The purpose of this study is to determine the efficacy of febuxostat in reducing serum urate levels in subjects with gout.

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and p...

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

The purpose of this study is to determine the long-term safety of febuxostat compared to allopurinol in reducing serum urate levels in subjects with gout.

Long-Term Safety of Febuxostat in Subjects With Gout.

The purpose of this study is to evaluate the long-term safety of febuxostat in maintaining serum urate levels within clinically acceptable levels in subjects with gout.

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

A Study comparing febuxostat, allopurinol and placebo in subjects with gout.

Search BioPortfolio:
Advertisement
Advertisement